A behind-the-scenes look inside three key trials involving Monsanto's weed killer Roundup, cancer, and the search for justice—written by an expert witness medical oncologist who lived it all. For years, Monsanto declared that their product Roundup, the world's most widely used weed killer, was safe. But that all changed in 2015, when the International Agency for Research on Cancer (IARC) analyzed data from scientific studies and concluded that glyphosate, the active ingredient in Roundup, is probably carcinogenic. The Environmental Protection Agency (EPA) disagreed, other regulatory agencies got involved, and scientists clamored to understand the link between glyphosate and cancer. Toxic Exposure tells the true story of numerous patients who developed non-Hodgkin lymphoma, a form of cancer, after using Roundup and their ensuing trials against Monsanto (now owned by Bayer, one of the largest agrochemical companies in the world). Written by Chadi Nabhan, MD, MBA, a cancer specialist, this is the only book written by an expert physician witness who testified in the first three trials against Monsanto. Dr. Nabhan takes the reader behind the scenes of these pivotal trials, explaining key features of the cases, including how Monsanto downplayed the IARC's scientific conclusions, may have worked to change how the EPA classified glyphosate, and conducted extensive PR campaigns designed to minimize the public's perception of the negative health effects of its product. He also provides details about the other expert witnesses who reviewed the evidence, analyzed the science, and stood up to this agricultural behemoth in the courtroom. Dr. Nabhan tells the inside story of corporate influence, courtroom drama, legal discourse, monumental verdicts, and the ensuing media frenzy surrounding this massive uncovering of the truth and the years of scientific and legal work that led up to it.

Chronic lymphocytic leukaemia (or "chronic lymphoid leukaemia"), known for short as CLL, is a type of leukaemia in which too many lymphocytes are produced. Although the malignant lymphocytes in CLL may look normal and mature, they are not and these cells may not cope effectively with infection. CLL is the most common form of leukaemia in adults. Men are twice as likely to develop CLL as women. However, the key risk factor is age. Over 75% of new cases are diagnosed in patients over age 50. This book presents important research from around the world in this field.